Shorts

Mohit Khera, MD, MBA, MPH, reacts to FDA announcement on TRT and idiopathic hypogonadism

The Expert APProach: Melissa Kestler, DNP, FNP-BC, on working in a stone clinic

James R. Porter, MD, on the telementoring capabilities of the Hugo RAS

Pearls & Perspectives: Normalizing sexual wellness conversations

Jennifer Miles-Thomas, MD, discusses areas of opportunity for urology APPs

The Expert APProach: Preparing the Next Generation of APPs

Akanksha Mehta, MD, on counseling men on vasectomy safety

Jonathan Anker, MD, on bladder-sparing approach in patients with MIBC

Daniel J. George, MD, on PTEN loss and prostate cancer prognosis

Alexandra Drakaki, MD, on misdiagnosis of bladder cancer in women

Pearls & Perspectives: What is “normal” urination frequency?

Giulia Almiron da R. Soares on social media and urology recruitment

Jared S. Winoker, MD, on research comparing CVAC 2.0 vs FANS

James R. Porter, MD, discusses haptics and the Hugo RAS system

Matthias Saar, MD, outlines the rationale for the phase 2 INDUCTA trial in prostate cancer

Pearls & Perspectives: The trouble with voiding diaries

Is PCNL dead? with Ben H. Chew, MD, MSc, FRCSC

Alicia Morgans, MD, discusses cancer control with enzalutamide, apalutamide

Bogdana Schmidt, MD, MPH, on who could benefit most from ICI plus BCG in high-risk NMIBC

Neha Vapiwala, MD, explores the biggest prostate cancer takeaways from ASCO GU 2026

Christopher Pieczonka, MD, on what’s next for NAI plus BCG in BCG-naïve NMIBC

Sara Coca Membribes, MD, on what’s needed to refine the role of BCG-ICI combinations in NMIBC

Jean-Nicolas Cornu, MD, PhD, FEBU, on the patient population of VAPEUR-RCT in BPH

Antoni Vilaseca Cabo, MD, on the pharmacokinetics of erda-iDRS in NMIBC

Daniel J. George, MD, on the need for caregiver support in prostate cancer

Brian F. Chapin, MD, on adding local therapy to systemic treatment in metastatic prostate cancer

Declan Murphy, MB, BCH, on the implications of PRIMARY2 study for prostate cancer diagnosis

Andrea Necchi, MD, on the SURE-02 trial evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab

Sam S. Chang, MD, MBA, on the significance of KEYNOTE-B15 data

James R. Porter, MD, on the modular architecture of the Hugo RAS